Pharmacy Medical News about Schizophrenia Risperidone

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Risperidone dose for schizophrenia
Cochrane Reviews, 10/21/09

Li C et al. – Reviewers searched the Cochrane Schizophrenia Groups Trials Register (July 2008) for all relevant references and selected all relevant randomised control trials (RCTs). Evidence from the present review indicates that the standard–lower dose range (>=4–<6 mg/day) seems optimal from viewpoints of clinical response and adverse effects, weak evidence supports a low dose (>=2–<4 mg/day) being efficient with less side–effects for people in their first episode of illness. A high dose range (>=10 mg/day) did not have much improvement over a standard–higher dose (>=6–<10 mg/day) or standard–lower dose, but had a higher risk of side–effects, especially movement disorders, and the same was found with an ultra low dose (<2 mg/day) due to an insufficient response. This review supports the use of dosages from low dose to standard–lower dose for different kinds of individual patients.

<< Previous
Palliative Oncology: Thalidomide

Next >>
FDA Approves New Test to Aid in the Diagnosis of Rheumatoid...